These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 22791509)

  • 1. Molecular markers in acute myeloid leukaemia.
    Kühnl A; Grimwade D
    Int J Hematol; 2012 Aug; 96(2):153-63. PubMed ID: 22791509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute myeloid leukemia].
    Döhner K; Paschka P; Döhner H
    Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
    Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
    Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
    Schnittger S; Schoch C; Kern W; Hiddemann W; Haferlach T
    Acta Haematol; 2004; 112(1-2):68-78. PubMed ID: 15179006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia.
    Tallman M
    J Natl Compr Canc Netw; 2018 May; 16(5S):656-659. PubMed ID: 29784749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute myeloid Leukemia].
    Braess J
    Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenge of risk stratification in acute myeloid leukemia with normal karyotype.
    Zaidi SZ; Owaidah T; Al Sharif F; Ahmed SY; Chaudhri N; Aljurf M
    Hematol Oncol Stem Cell Ther; 2008; 1(3):141-58. PubMed ID: 20063545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
    Hirsch P; Tang R; Abermil N; Flandrin P; Moatti H; Favale F; Suner L; Lorre F; Marzac C; Fava F; Mamez AC; Lapusan S; Isnard F; Mohty M; Legrand O; Douay L; Bilhou-Nabera C; Delhommeau F
    Haematologica; 2017 Jul; 102(7):1227-1237. PubMed ID: 28302711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
    DiNardo C; Lachowiez C
    Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
    Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
    Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene.
    Ommen HB; Hokland P; Haferlach T; Abildgaard L; Alpermann T; Haferlach C; Kern W; Schnittger S
    Br J Haematol; 2014 Jun; 165(5):618-28. PubMed ID: 24611505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.